The 90-Day Window: How Patients Can Block Political Interference in Science

The proposed White House rule giving political appointees final say over individual research grants is currently sitting in a 90-day public comment period. It is not yet law. That window—roughly three months—is the same kind of narrow opening that allowed one well-organized patient advocacy group to kill a similar policy change in 2017. According to an April 2025 report in Scientific American, the new rule would let political appointees override scientific peer review and veto funding for specific studies, including those investigating treatments for cancer, Alzheimer's, and Parkinson's. The stated rationale is to ensure grant alignment with agency priorities. The practical effect is that a study's scientific merit could be secondary to whether it fits a political agenda. Most observers assume the most effective opposition will come from universities, scientific societies, or industry lobbies. The evidence from 2017 suggests otherwise. That year, the NIH proposed a "Patient-Focused Drug Development" guidance change that would have similarly centralized decision-making. A 72-hour campaign by ACT UP New York—a small, focused coalition of HIV patients—generated roughly 15,000 public comments, and the policy was withdrawn. The key was not institutional weight, but a concentrated surge of personal stories from people who could describe, in concrete terms, how the policy would affect their treatment timelines. That same dynamic could apply here. The public comment period for the current rule offers a structured mechanism for patients to intervene. The playbook already exists: advocacy groups need to identify patients whose conditions depend on grant-funded studies, equip them with a clear narrative template, and mobilize them to submit within the window. A single effective comment might read: "I am a stage 3 melanoma patient currently qualifying for a clinical trial funded by NIH grant R01-XX. If political appointees can block that grant, my chance at a potential cure disappears. I ask the administration to maintain scientific peer review as the sole basis for funding decisions." Specific, personal, tied to a real grant. This is not a guaranteed victory. The current administration may be less responsive to public pushback than its predecessor was in 2017, and the rule may be designed precisely to insulate political decisions from comment. But the structure of the regulatory process gives patients a lever, not just a plea. The 90-day window is the moment when a patient's personal story carries procedural weight. The question is whether advocacy groups will organize around that mechanism with the same intensity ACT UP did eight years ago.